Drugs News and Research

RSS

Complementary medicine to save millions: Report

According to a new report substituting pharmaceutical antidepressants with St John’s Wort could save the health system $50 million a year. This research was conducted by Access Economics for the National Institute of Complementary Medicine (NICM) at the University of Western Sydney. It showed that cost effectiveness of complementary and alternative therapies have the potential to cut costs without compromising patient outcomes.

13 Sep 2010

AstraZeneca, UCL collaborate to identify new therapeutic tools to modulate regenerative capacity of stem cells

AstraZeneca and UCL (University College London) today announced that they have entered into a collaboration to develop regenerative medicines for diabetic retinopathy (DR).

13 Sep 2010

Study finds antibiotic safe for treatment of stroke and good companion therapy for tPA

An antibiotic appears to be a safe treatment for stroke and a good companion therapy for tPA, the clot buster that is currently the only FDA-approved drug therapy, researchers report.

13 Sep 2010

Counterfeit drugs become growing problem

"Last year, nearly 1,700 incidents of counterfeit drugs were reported worldwide, triple the number in 2004, says the Pharmaceutical Security Institute (PSI), a group funded by drugmakers," USA Today reports. "Estimates for the size of the counterfeit drug market range from $75 billion to $200 billion a year. The market is likely much bigger because many cases are hard to detect.

13 Sep 2010

Genomas awarded method patent for PhyzioGenomics Technology

Genomas®, a biomedical company advancing DNA-Guided Medicine, has been awarded US Patent 7,747,392, entitled Physiogenomic Method for Predicting Clinical Outcomes of Treatment in Patients by the US Patent and Trademark Office.

13 Sep 2010

Synta expands STA-9090 Phase 2 clinical trial in NSCLC

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it was expanding its Phase 2 clinical trial of STA-9090 in patients with Stage IIIB and Stage IV non-small cell lung cancer (NSCLC) from up to 69 patients to up to 146 patients based on encouraging activity observed in the first stage of the two stage clinical trial.

13 Sep 2010

Relypsa completes $70M Series B financing

Relypsa, Inc., a biopharmaceutical company developing non-absorbed polymeric drugs, today announced the completion of a Series B financing totaling $70 million. OrbiMed Advisors, LLC, led the financing with participation from existing Relypsa investors New Leaf Venture Partners, 5AM Ventures, Delphi Ventures, Sprout Group and Mediphase Venture Partners.

13 Sep 2010

FDA updates Shire's ProAmatine medicine for symptomatic orthostatic hypotension treatment

Shire, the global specialty biopharmaceutical company, announces that the United States Food and Drug Administration today posted an update on its website related to ProAmatine (known generically as midodrine), a medicine approved for the treatment of symptomatic orthostatic hypotension.

13 Sep 2010

AB SCIEX, University of Melbourne join to develop drug metabolism studies of biopharmaceuticals

AB SCIEX, a global leader in life science analytical technologies, and the University of Melbourne today announced a joint technology development project to improve drug metabolism studies of biopharmaceuticals.

13 Sep 2010

Vical's TransVax CMV vaccine achieves key endpoints in Phase 2 trial in immunocompromised HCT recipients

Vical Incorporated announced today the achievement of key efficacy, immunogenicity and safety results in a Phase 2 trial, establishing its TransVax™ cytomegalovirus (CMV) vaccine as the first to provide evidence of protection in immunocompromised hematopoietic cell transplant (HCT) recipients, and defining a potential pathway for further development.

13 Sep 2010

Debiopharm, Aurigene commence IND enabling studies for Debio 0617 inhibitor

Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative prescription drugs that target unmet medical needs, and Aurigene Discovery Technologies Ltd., a Bangalore based fully integrated, global biotech focused on small molecule and peptide drug discovery and development from target identification and validation to pre IND drug candidates, today announced the successful nomination of a development candidate, Debio 0617, a novel inhibitor of an undisclosed oncology pathway.

13 Sep 2010

CRT agrees with AstraZeneca for AZD-3965 clinical trial

Cancer Research UK and Cancer Research Technology the charity's development and commercialisation arm have reached an agreement with AstraZeneca to take compound AZD-3965 a first-of-its-kind experimental drug to potentially treat a range of cancers into clinical trial.

13 Sep 2010

Researchers find amyloid precursor protein function in Alzheimer's disease

In people with Alzheimer's, the brain becomes riddled with clumps of protein, forming what are known as amyloid plaques. Now, a report appearing in the September 17th print issue of Cell appears to have found a function for the amyloid precursor protein that yields the prime ingredient in those plaques.

13 Sep 2010

Researchers develop KU-32 drug to prevent diabetic peripheral neuropathy

A drug developed at the University of Kansas has the potential to stop a debilitating condition of diabetes that often leads to pain in the extremities and even amputations, KU researchers have found.

13 Sep 2010

Ill. prepares high risk pool; Calif. residents struggle with rising health care costs

"At first glance, the new Pre-existing Condition Insurance Plan sounds like welcome relief for jobless Illinoisans who have serious medical issues and are struggling with the loss of employer financed health care. The federally financed $5 billion plan $196 million of which is earmarked for Illinois provides an affordable health insurance option to people who previously were limited to the far more expensive, state run Illinois Comprehensive Health Insurance Plan.

13 Sep 2010

MRSA infection hVISA linked to mortality

A MRSA infection with a reduced susceptibility to the potent antibiotic drug vancomycin is linked to high mortality, according to a Henry Ford Hospital study.

12 Sep 2010

Today's Opinions: Democrats running away from health care; One company's success with insurance; Calif.'s effort on mental health parity

Facing a grim November, Democrats are now running on another quarter-baked stimulus plan and the specter of John Boehner's perpetual tan, instead of the bill they spent more than a year debating and hailed as the liberal triumph of the century. Democrats now barely mention ObamaCare on the trail—unless they're trashing it (9/9).

10 Sep 2010

McGill researchers pioneer anesthetics via videoconferencing

Videoconferences may be known for putting people to sleep, but never like this. Dr. Thomas Hemmerling and his team of McGill's Department of Anesthesia achieved a world first on August 30, 2010, when they treated patients undergoing thyroid gland surgery in Italy remotely from Montreal. The approach is part of new technological advancements, known as 'Teleanesthesia', and it involves a team of engineers, researchers and anesthesiologists who will ultimately apply the drugs intravenously which are then controlled remotely through an automated system.

10 Sep 2010

NAADAC and Hazelden partner to improve treatment for co-occurring disorders

NAADAC, the Association for Addiction Professionals, and Hazelden, the national nonprofit focused on addiction treatment, prevention and recovery announced today a new strategic partnership focused on improving the treatment of co-occurring disorders. The partnership announcement was made by NAADAC Executive Director Cynthia Moreno Tuohy during the National Conference on Addiction Disorders in Washington, D.C.

10 Sep 2010

Instem announces Centrus Solution Suite for enterprise information integration in early drug development

Instem, a leading provider of early drug development software solutions, announced today details of their newest product line, Centrus™, for enterprise information integration in early drug development. Centrus provides a single, secure environment to access, harmonize and use early drug development information from a variety of sources, including current data acquisition systems, legacy systems, warehouses, partner and contract research applications, to meet the rapidly-expanding needs of life science organizations for data-driven decision making.

10 Sep 2010

Drugs News and Research

Complementary medicine to save millions: Report

AstraZeneca, UCL collaborate to identify new therapeutic tools to modulate regenerative capacity of stem cells

Study finds antibiotic safe for treatment of stroke and good companion therapy for tPA

Counterfeit drugs become growing problem

Genomas awarded method patent for PhyzioGenomics Technology

Synta expands STA-9090 Phase 2 clinical trial in NSCLC

Relypsa completes $70M Series B financing

FDA updates Shire's ProAmatine medicine for symptomatic orthostatic hypotension treatment

AB SCIEX, University of Melbourne join to develop drug metabolism studies of biopharmaceuticals

Vical's TransVax CMV vaccine achieves key endpoints in Phase 2 trial in immunocompromised HCT recipients

Debiopharm, Aurigene commence IND enabling studies for Debio 0617 inhibitor

CRT agrees with AstraZeneca for AZD-3965 clinical trial

Researchers find amyloid precursor protein function in Alzheimer's disease

Researchers develop KU-32 drug to prevent diabetic peripheral neuropathy

Ill. prepares high risk pool; Calif. residents struggle with rising health care costs

MRSA infection hVISA linked to mortality

Today's Opinions: Democrats running away from health care; One company's success with insurance; Calif.'s effort on mental health parity

McGill researchers pioneer anesthetics via videoconferencing

NAADAC and Hazelden partner to improve treatment for co-occurring disorders

Instem announces Centrus Solution Suite for enterprise information integration in early drug development

Drug Discovery - Second Edition eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News